Read this article:
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Originally posted here:
NeuroStar® Advanced Therapy Enhanced With Wi-Fi Capabilities

Original post:
GreenLight Biosciences announces $109 million financing

Read the original here:
Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th

See the rest here:
Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

See original here:
Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

Continued here:
SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial

Read more:
Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments

See the original post here:
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to...

Go here to read the rest:
Stephen Bardin to Join atai Life Sciences as CFO Designate

Link:
Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)

See the article here:
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

The rest is here:
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

See the original post here:
ProKidney to present at upcoming investor conferences

Here is the original post:
TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference

Read the original:
Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors

Read more:
TFF Pharmaceuticals to Participate at the H.C. Wainwright Global Investment Conference

Read more here:
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Here is the original post:
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

See the original post here:
Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th...